Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
Thursday, April 24, 2025 2 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will hold a conference call on April 29, 2025, at 8:30 a.m. Eastern Time to present its first quarter 2025 financial results and recent developments. The conference call will be accessible via a live webcast on the company's website, with registration available for telephone participants. Kiniksa is dedicated to developing therapeutic solutions for diseases with significant unmet needs, particularly in the cardiovascular domain.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is reporting progress in its portfolio execution.
The company focuses on meeting unmet medical needs in cardiovascular health.
The upcoming financial report could indicate positive developments for investors.
Full Press Release Details
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.